At the onset of the COVID-19 pandemic, urgency drove quick decisions in vaccine development. Companies like Moderna leveraged innovative mRNA technology, leading to swift funding and contract signings just days after the outbreak was recognized. This chapter highlights the remarkable speed and collaboration that characterized the early response to an unprecedented health crisis.
